Medtimo files patent infringement complaint against Allurion

Medtimo, a wholly owned subsidiary of Biorad Medisys Private Limited, has filed a patent infringement complaint in the US District Court of the District of Delaware against Allurion Technologies.

Medtimo’s complaint claims Allurion's gastric balloon system infringes upon Medtimo's intellectual property. This definitive action follows Allurion’s recent unsuccessful challenge of Medtimo’s patent rights in the US Patent and Trademark Office (USPTO). The complaint alleges that Allurion has infringed three key Medtimo patents, and is a refiling of a previous complaint filed in 2023, but with two additional patents that were awarded by the USPTO to Medtimo later in 2023 and 2024, affirming Medtimo’s commitment to its strong intellectual property portfolio.

The complaint specifically alleges infringement on three key patents, including US Patent No 10,463,520, US Patent No 11,779,482, and US Patent No 11,974,934, and Medtimo stands fully prepared to vigorously protect its valuable technology.

“Medtimo has a long-standing commitment to developing and protecting our intellectual property, which is a cornerstone of our business,” said Paul Hickey, CEO of Medtimo. “Allurion's products, including their gastric balloon system, allegedly utilize technology covered by our patents, and we are prepared to protect our innovations against infringers. This is a necessary step to protect our balloon system technology and the significant investments we've made in research and development, solidifying our position as a leader in the US market.”